CLINICAL TRIALS PROFILE FOR DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER
✉ Email this page to a colleague
All Clinical Trials for Dextrose 2.5% In Half-strength Lactated Ringer's In Plastic Container
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00113685 ↗ | Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 2003-04-01 | The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness. |
| NCT00113685 ↗ | Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury | Completed | University of Washington | N/A | 2003-04-01 | The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness. |
| NCT00181077 ↗ | Hypertonic Saline Use in Preeclampsia | Completed | Johns Hopkins University | Phase 1 | 2003-06-01 | To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia. |
| NCT00311519 ↗ | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects | Completed | Halozyme Therapeutics | Phase 4 | 2005-11-01 | The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one. |
| NCT00334360 ↗ | Dexmed/Buspirone Synergism on Shivering | Completed | The Cleveland Clinic | Phase 4 | 2004-09-01 | The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia. The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration. Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dextrose 2.5% In Half-strength Lactated Ringer's In Plastic Container
Condition Name
Clinical Trial Locations for Dextrose 2.5% In Half-strength Lactated Ringer's In Plastic Container
Trials by Country
Clinical Trial Progress for Dextrose 2.5% In Half-strength Lactated Ringer's In Plastic Container
Clinical Trial Phase
Clinical Trial Sponsors for Dextrose 2.5% In Half-strength Lactated Ringer's In Plastic Container
Sponsor Name
